Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stribild in HIV-1 Infected Adolescents
NCT01721109Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2012
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Primary endpoints: Area Under the Plasma Concentration-Time Curve Over the Dosing Interval at Day 10 and Incidence of Treatment-Emergent Serious Adverse Events and All Treatment-Emergent Adverse Events. Started Dec 2012; status: completed.
02
Drugs
emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01721109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01721109.